Suchergebnisse - "Elizabeth R. Plimack"

1

Re: Michael B. Atkins, Elizabeth R. Plimack, Igor Puzanov, et al. Axitinib in Combination with Pembrolizumab in Patients with Advanced Renal Cell Cancer: A Non-randomised, Open-label, Dose-finding, and Dose-expansion Phase 1b Trial. Lancet Oncol 2018;19:405–15

von: Di Nunno, Vincenzo

2018, in: Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise

Wird geladen...
2

Re: Jens Bedke, Brian I. Rini, Elizabeth R. Plimack, et al. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. Eur Urol. 2022;82:427–39

von: Zhao, Binghao

2022, in: Phase transition and alternation in a model of perceptual bistability in the presence of Lévy noise

Wird geladen...
3

Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer

von: Plimack ER

2012, in: Biologics: Targets & Therapy

Wird geladen...
4

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

von: Alessia Cimadamore

2023, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
5

Role of immunotherapy in localized muscle invasive urothelial cancer

von: Jasmeet Kaur

2021, in: Therapeutic Advances in Medical Oncology

Wird geladen...
6

Muscle-invasive urothelial bladder cancer: an update on systemic therapy

von: Hayley Knollman

2015, in: Therapeutic Advances in Urology

Wird geladen...
7

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

von: Asim Amin

2018, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
8

Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer

von: Jeffrey S. Damrauer

2022, in: Nature Communications

Wird geladen...
9

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database

von: Gabriella Del Bene

2018, in: Frontiers in Oncology

Wird geladen...
10

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial

von: Howard Gurney

2020, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
11

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

von: Howard Gurney

2020, in: ESMO Open

Wird geladen...
12

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

von: Gary D Steinberg

2021, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
13

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

von: Asim Amin

2019, in: Journal for ImmunoTherapy of Cancer

Wird geladen...
14

Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer

von: David Liu

2017, in: Nature Communications

Wird geladen...

Nicht das Richtige dabei?

Schreiben Sie uns!